Get the Daily Brief
Latest Biotech News
Takeda and Alkermes Advance Narcolepsy Treatments with Positive Trial Data
Takeda and Alkermes revealed encouraging clinical trial data for novel orexin receptor agonists targeting narcolepsy. Takeda’s Phase 3 trials for oveporexton showed significant improvement in...
Servier Acquires Fragile X Syndrome Candidate KER-0193 for Up to $450 Million
French pharmaceutical company Servier announced an acquisition deal with Kaerus Bioscience for their Fragile X syndrome drug candidate KER-0193. The oral small molecule, a BK channel modulator,...
Rapport Therapeutics’ Seizure Drug RAP-219 Hits Phase 2 Primary Endpoint, Shares Surge
Rapport Therapeutics reported strong mid-stage clinical results for RAP-219, an experimental drug targeting drug-resistant focal onset seizures. The single-arm Phase 2a trial demonstrated a 78%...
AI and Machine Learning Accelerate Bioprocessing and Drug Discovery
Recent bibliometric analysis reveals exponential growth in AI applications within biotechnology, driven by machine learning, natural language processing, and computational advances. Researchers...
RedC Biotech Develops Lab-Grown Blood to Address Global Supply Shortages
Israel-based startup RedC Biotech is pioneering the large-scale production of lab-grown red blood cells from stem cells, aiming to provide a universal blood type and alleviate worldwide shortages....
Novel Metabolic Pathway Enables Cancer Cells to Sustain Growth via β-Hydroxybutyrate
Van Andel Institute researchers discovered an alternative metabolic route cancer cells use to convert the ketone β-hydroxybutyrate (β-OHB) into acetyl-CoA, a crucial precursor for fatty acid and...
DARWIN Project Develops Genetic Fingerprinting to Detect Gene-Edited Organisms
Researchers at the Belgian Federal Institute Sciensano, as part of the DARWIN project, developed proof-of-concept next-generation detection technology for identifying genome-edited organisms...
Summit Therapeutics’ Lung Cancer Drug Fails Key Survival Endpoint – FDA Approval in Doubt
Summit Therapeutics’ bispecific antibody ivonescimab, targeting PD-1 and VEGF pathways, showed statistically significant progression-free survival improvement but failed to demonstrate overall...
Rapport Therapeutics’ Seizure Drug RAP-219 Delivers Strong Phase 2 Results, Stock Triples
Rapport Therapeutics reported robust Phase 2 data for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator for drug-resistant focal onset seizures. The open-label study demonstrated a...
BioNTech and Bristol Myers Tout Promising PD-L1xVEGF Bispecific Data in Small Cell Lung Cancer
BioNTech and Bristol Myers Squibb unveiled the first global data for their PD-L1xVEGF bispecific antibody in combination with chemotherapy for small cell lung cancer. Mid-stage results...
Dianthus Therapeutics Reports Positive Phase 2 Data in Myasthenia Gravis, Sets Stage for Phase 3
Dianthus Therapeutics disclosed successful Phase 2 trial outcomes for claseprubart, a selective complement inhibitor targeting generalized myasthenia gravis. The antibody met multiple efficacy...
Epigenic Therapeutics Locks $60M Series B to Advance CRISPR-Based Gene Therapies
China’s Epigenic Therapeutics secured $60 million in Series B financing to propel clinical development of its lead gene therapy candidates EPI-003, targeting chronic hepatitis B, and EPI-001 for...
NRG Therapeutics Raises $67M to Propel Mitochondrial-Targeting Drugs for Neurodegeneration
UK-based NRG Therapeutics secured £50 million ($67 million) in an oversubscribed Series B round to advance its small-molecule regulators of the mitochondrial permeability transition pore (mPTP)...
Advances in AI and Data Integration Transform Bioprocessing and Drug Discovery
Artificial intelligence is rapidly reshaping biotech industries, from drug discovery to bioprocess manufacturing. A bibliometric study uncovered exponential growth in AI-related biotech...
Cancer Metabolism: Alternative Fuel Pathways and Novel Targeted Therapies Unveiled
Recent research from the Van Andel Institute revealed that cancer cells metabolize ketones via a non-canonical route to produce acetyl-CoA, implicating metabolic flexibility in tumor...
Julius Clinical Expands Footprint into Spain and Germany to Boost Global Trial Capabilities
Julius Clinical strategically launched new operations in Spain and Germany, aiming to enhance regulatory expertise and access to patients in key European markets. The Netherlands-based CRO cites...
Rapport Therapeutics' Seizure Drug Surges Amid Phase 2 Trial Win
Rapport Therapeutics reported striking Phase 2 data for its experimental epilepsy drug RAP-219, showing a median 78% reduction in seizure frequency across 30 patients. The open-label trial used...
Small Cell Lung Cancer Therapy Shows Mixed Phase 3 Results
Summit Therapeutics and partners presented updated data from the Phase 3 Harmoni trial evaluating ivonescimab combined with chemotherapy in advanced lung cancer. While early results from patients...
Emerging Therapies Advance Non-Small Cell Lung Cancer Care
Recent large-scale trials disclosed at the 2025 IASLC World Conference on Lung Cancer demonstrate significant improvements in NSCLC therapy. Aumolertinib combined with chemotherapy showed superior...
Dianthus Therapeutics Advances Myasthenia Gravis Treatment with Phase 2 Success
Dianthus Therapeutics announced positive Phase 2 data for its selective complement inhibitor, claseprubart, targeting generalized myasthenia gravis (gMG). The antibody met multiple efficacy...